NDI Notifications Take Center Stage In FDA's Evaluation Of DSHEA
Executive Summary
FDA's notice for a May 16 public meeting say it intends to ensure its "regulatory framework is flexible enough to adequately evaluate product safety without unnecessarily restricting innovation." But FDA makes clear adherence with its NDI notification requirement is focus of the spurring improvement in VMS product industry's overall compliance with regulatory framework established by DSHEA.
You may also be interested in...
NDI Notification Costs Estimate Unchanged In US, But Delivered With Guidance Surprise
NDIN guidance won’t come a day too soon for supplement industry, but revised guidances from comments on a 2016 draft could be based on dated information.
FDA Expects Closing Gap On NDI Notifications To Open Window Wider On Supplements Sold In US
FDA regulatory framework for VMS product manufacturing and marketing provides little pre-market transparency into what’s available in US, but it’s clear from post-market monitoring by the Office of Dietary Supplement Programs that compliance with the NDI notification requirement is lax.
US FDA Allows Supplement Firms More Time To Submit NDI Notifications, And For It To Respond
More time for notifications than current deadline of at least 75 days before NDI-containing product is offered for sale in US doesn’t solve problems with FDA’s management of NDI regulation, say trade groups.